Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.42 |
| ▸ | CA2 | P00918 | 8/20 | 0.42 |
| ▸ | ACHE | P22303 | 6/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 4/20 | 0.33 |
| ▸ | HTR2A | P28223 | 4/20 | 0.33 |
| ▸ | DRD3 | P35462 | 4/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | G6PD | P11413 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11137690 | 0.78 | CA1 (0.56) | CA1CA2ACHECA12CA7 | |
| SCHEMBL31195376 | 0.76 | CA1 (0.40) | CA1CA2ACHECA12CA7 | |
| SCHEMBL1346986 | 0.76 | CA12 (0.46) | CA1CA2CA12CA7CA14 | |
| SCHEMBL181007 | 0.76 | CA12 (0.46) | CA1CA2CA12CA7CA14 | |
| SCHEMBL1950933 | 0.76 | CA12 (0.46) | CA1CA2CA12CA7CA14 | |
| SCHEMBL3220451 | 0.75 | CA1 (0.45) | CA1CA2ACHECA12CA7 | |
| SCHEMBL4361760 | 0.75 | CA1 (0.42) | CA1CA2ACHECA12CA7 | |
| Hydrochloric Acid SCHEMBL5006769 | 0.74 | CA12 (0.44) | CA1CA2CA12CA7CA14 | |
| Hydrochloric Acid SCHEMBL1226560 | 0.74 | CA12 (0.44) | CA1CA2CA12CA7CA14 | |
| SCHEMBL12764009 | 0.72 | SMYD3 (0.46) | CA1CA2CA12CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2401274-B1 | IMIDAZO[1,2-A]PYRIDINES AS JNK MODULATORS | HOFFMANN LA ROCHE (CH) | 2014-10-22 | — | — | EP | disclosed |
| US-8569306-B2 | JNK modulators | HOFFMANN-LA ROCHE, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2401274-A1 | IMIDAZO [1, 2 -A]PYRIDINES AS JNK MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| US-20110306618-A1 | JNK Modulators | BUETTELMANN BERND (DE) | 2011-12-15 | — | — | US | disclosed |
| WO-2010097335-A1 | IMIDAZO [1, 2 -A] PYRIDINES AS JNK MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306618-A1 | JNK Modulators | MAPK3, MAPK1, MAPK4 | CA1 4363/4885CA2 2285/4885ACHE 4680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.